Research

BYD (1211 HK)

Take into account BYD’s hidden debt and its gearing rises from 74% to 122%. This raises the possibility of further capital increases in light of substantial cash outflows and deteriorating profitability due to fast declining subsidies. These purchase subsidies doubled in FY16, contributing over 40% of BYD’s revenue from electric vehicles, which led to a near 80% rise in profits. However, subsidies will be gone in three years. The company is already feeling the impact; analysts have reduced FY17 profit expectations by almost 20% so far this year. Add into the mix the company’s expensive valuation and a propensity to…
Read more ›

Log In

Insights

SHORT SELLER’S SNAPSHOT

TIAN GE (1980 HK): Reasons for concern

Gillem Tulloch · 17 August 2017

The seventh short seller’s report in Hong Kong this year has targeted social video platform operator, Tian Ge (Mkt Cap US$1bn). The report was written by anonymous short seller, Emerson Analytics, whose 100% success rate for its six previous reports should be cause for concern in itself. Emerson alleges that more than half of Tian Ge’s revenues have been faked and this can be proven by monitoring its market share of various online metrics. Unfortunately, there are good reasons for concern. Tian Ge has many of the hallmarks of a fraud in that it is highly profitable and there is…
Read more ›

NEWSLETTER 15:

Hong Kong needs short-sellers

Gillem Tulloch · 14 August 2017

It’s not just because Hong Kong allows short-selling that there are so many short-sellers’ reports, it’s because (by our estimates) Hong Kong is the corporate fraud capital of the world. A small but meaningful percentage of mainland companies seem predisposed to defrauding investors. In general, the sellside is not incentivised to uncover these frauds while auditors and regulators have been unsuccessful in spotting them. Meanwhile, as an accounting research firm, GMT Research is able to detect companies we suspect of being fake cash flow frauds but cannot definitely prove it. Given the expense involved in researching and uncovering frauds, short-sellers are…
Read more ›

CARILLION (CLLN LN)

Worrying parallels

Gillem Tulloch · 19 July 2017

You might be wondering what a UK contractor’s woes have to do with Asia. First, Carillion’s has a similar supplier payment arrangement to Sinopharm but, unlike Sinopharm, it does not reclassify repayments as a financing activity which materially overstates Sinopharm’s operating cash flow. This re-enforces the view presented in our recent report that Sinopharm’s cash flow statement misrepresents its financial position. Second, Carillion’s surprise share price collapse shows that subjective contract accounting can inflate reported profits and asset prices. It is only when banks want their money back that shareholders find out there’s nothing left. The UK contractors might look…
Read more ›

Free Newsletter

GET OUR FREE NEWSLETTER

Input your email address below to sign-up to our free newsletter.